IDEXX LABORATORIES INC /DE — Form 8-K
Filed August 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
IDEXX reported Q2 2026 revenue of $1,217M (+10% reported, +9% organic) with CAG Diagnostics recurring revenue growing 11% reported and 10% organic. The company narrowed full-year 2026 revenue guidance to $4,700M–$4,745M (midpoint raised $5M) and raised EPS outlook to $14.69–$14.94 (midpoint +$0.14), reflecting operational outperformance offset by $15M FX headwinds. Operating margin expanded 140 bps reported (110 bps comparable) to 35.0%, and IDEXX inVue Dx surpassed 9,000 installed units with 1,600+ placements in Q2.
Why this rating
Modest raise of $5M revenue guidance (0.1% of $4.7B annual revenue) is immaterial in absolute terms; organic growth acceleration and margin expansion are encouraging but routine for execution track record. Event is ordinary periodic guidance refinement relative to company scale.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.